Analyzing Gilead Sciences’ HIV Portfolio
Gilead Sciences’ (GILD) total HIV sales got a boost from the US market. The HIV product sales in the United States increased from $2.52 billion in the third quarter of 2017 to $3.0 billion in the third quarter. The HIV product sales in Europe decreased from $656.0 million in the third quarter of 2017 to $584.0 million in the third quarter. The sales in other international markets decreased from $156.0 million in the third quarter of 2017 to $138.0 million in the third quarter. Gilead Sciences’ Biktarvy generated US sales of $375. ...